Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 2
Submit an article Journal homepage
165
Views
0
CrossRef citations to date
0
Altmetric
Review

Drug-Mediated and Cellular Immunotherapy in Multiple Myeloma

David S Ritchie1 Haematology & Immunology Translational Research Laboratory, Cancer Immunology Research Program;2 Department of Haematology & Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A‘Beckett St, East Melbourne, VIC8000, Australia.Tel.: +61 396 561 118 Fax: +61 396 561 [email protected];3 University of Melbourne, Parkville, Victoria, Australia
,
Hang Quach1 Haematology & Immunology Translational Research Laboratory, Cancer Immunology Research Program;4 Monash Medical Centre, Clayton, Victoria, Australia
,
Kate Fielding1 Haematology & Immunology Translational Research Laboratory, Cancer Immunology Research Program
&
Paul Neeson1 Haematology & Immunology Translational Research Laboratory, Cancer Immunology Research Program
Pages 243-255 | Published online: 05 Mar 2010

Bibliography

  • Jagannath S , BarlogieB: Autologous bone marrow transplantation for multiple myeloma.Hematol. Oncol. Clin. North Am.6 , 437–449 (1992).
  • Attal M , HarousseauJL, StoppaAMet al.: Intensive therapy for high grade multiple myeloma(MM).N. Engl. J. Med.335 , 91–97 (1996).
  • Richardson PG , SonneveldP, SchusterMWet al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N. Engl. J. Med.352 , 2487–2498 (2005).
  • Kumar SK , RajkumarSV, DispenzieriAet al.: Improved survival in multiple myeloma and the impact of novel therapies.Blood111(5) , 2516–2520 (2008).
  • Rajkumar SV : Treatment of myeloma: cure vs control.Mayo Clin. Proc.83(10) , 1142–1145 (2008).
  • Zou W : Immunosuppressive networks in the tumour environment and their therapeutic relevance.Nat. Rev. Cancer5(4) , 263–274 (2005).
  • Brown RD , PopeB, MurrayAet al.: Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80(B7–1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10.Blood15 , 98(10) , 2992–2998 (2001).
  • Ratta M , FagnoniF, CurtiAet al.: Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.Blood100(1) , 230–237 (2002).
  • Hegde S , PahneJ, Smola-HessS: Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-κB binding activity and CCR7 expression.FASEB J.18(12) , 1439–1441 (2004).
  • Takahashi A , KonoK, IchiharaF, SugaiH, FujiiH, MatsumotoY: Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines.Cancer Immunol. Immunother.53(6) , 543–550 (2004).
  • Cook G , CampbellJD, CarrCE, BoydKS, FranklinIM: Transforming growth factor b from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes.J. Leukoc. Biol.66(6) , 981–988 (1999).
  • Brimnes MK , SvaneIM, JohnsenHE: Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma.Clin. Exp. Immunol.144(1) , 76–84 (2006).
  • Jarahian M , WatzlC, IssaY, AltevogtP, MomburgF: Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells.Int. J. Cancer120(12) , 2625–2634 (2007).
  • Smyth MJ , GodfreyDI, TrapaniJA: A fresh look at tumor immunosurveillance and immunotherapy.Nat. Immunol.2(4) , 293–299 (2001).
  • Pratt G , GoodyearO, MossP: Immunodeficiency and immunotherapy in multiple myeloma.Br. J. Haematol.138(5) , 563–579 (2007).
  • Munshi NC : Immunoregulatory mechanisms in multiple myeloma.Hematol. Oncol. Clin. North Am.11(1) , 51–69 (1997).
  • Rawstron AC , DaviesFE, OwenRGet al.: B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors.Br. J. Haematol.100(1) , 176–183 (1998).
  • Mills KH , CawleyJC: Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage.Br. J. Haematol.53(2) , 271–275 (1983).
  • Ogawara H , HandaH, YamazakiTet al.: High Th1/Th2 ratio in patients with multiple myeloma.Leuk. Res.29(2) , 135–140 (2005).
  • Frassanito MA , CusmaiA, DammaccoF: Deregulated cytokine network and defective Th1 immune response in multiple myeloma.Clin. Exp. Immunol.125(2) , 190–197 (2001).
  • Quach H , RitchieD, NeesonPet al.: Lymphoid subsets and regulatory T cell profiles in patients with relapsed multiple myeloma in a subset of patients enrolled in the REVLITE trial(abstract). Presented at: Haematology Society of Australia and New Zealand Annual Scientific Meeting. Perth, Australia, October (2008).
  • Maecker B , AndersonKS, von Bergwelt-Baildon MS et al.: Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br. J. Haematol.121(6) , 842–848 (2003).
  • Dhodapkar MV , GellerMD, ChangDHet al.: A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.J. Exp. Med.197(12) , 1667–1676 (2003).
  • Subklewe M , Sebelin-WulfK, BeierCet al.: Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.Hum. Immunol.68 , 147–155 (2007).
  • Curiel TJ : Tregs and rethinking cancer immunotherapy.J. Clin. Invest.117(5) , 1167–1174 (2007).
  • Chen ML , PittetMJ, GorelikLet al.: Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo.Proc. Natl Acad. Sci. USA102(2) , 419–424 (2005).
  • Nishikawa H , JagerE, RitterG, OldLJ, GnjaticS: CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.Blood106(3) , 1008–1011 (2005).
  • Yang ZZ , NovakAJ, ZiesmerSC, WitzigTE, AnsellSM: Attenuation of CD8+ T-cell function by CD4+CD25+ regulatory T cells in B-cell non-Hodgkin‘s lymphoma.Cancer Res.66(20) , 10145–10152 (2006).
  • Trzonkowski P , SzmitE, MysliwskaJ, DobyszukA, MysliwskiA: CD4+ CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction.Clin. Immunol.112(3) , 258–267 (2004).
  • Wolf AM , WolfD, SteurerM, GastlG, GunsiliusE, Grubeck-LoebensteinB: Increase of regulatory T cells in the peripheral blood of cancer patients.Clin. Cancer Res.9(2) , 606–612 (2003).
  • Beyer M , SchultzeJL: Regulatory T cells in cancer.Blood108(3) , 804–811 (2006).
  • Ichihara F , KonoK, TakahashiA, KawaidaH, SugaiH, FujiiH: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.Clin. Cancer Res.9(12) , 4404–4408 (2003).
  • Curiel TJ , CoukosG, ZouLet al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.Nat. Med.10(9) , 942–949 (2004).
  • Joshua DE , BrownRD, HoPJ, GibsonJ: Regulatory T cells and multiple myeloma.Clin Lymphoma Myeloma8(5) , 283–286 (2008).
  • Prabhala RH , NeriP, BaeJEet al.: Dysfunctional T regulatory cells in multiple myeloma.Blood107(1) , 301–304 (2006).
  • Quach H , RitchieD, NeesonPet al.: Regulatory T cells(Treg) are depressed in patients with relapsed/refractory multiple myeloma(MM) and increases towards normal range in responding patients treated with lenalidomide.Blood112 , 1696A (2008).
  • Beyer M , KochanekM, GieseTet al.: In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.Blood107(10) , 3940–3949 (2006).
  • Feyler S , von Lilienfeld-Toal M, Jarmin S et al.: CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4-CD8- αβTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br. J. Haematol.144(5) , 686–695 (2009).
  • Dhodapkar KM , BarbutoS, MatthewsPet al.: Dendritic cells mediate the induction of polyfunctional human IL17-producing cells(Th17-1 cells) enriched in the bone marrow of patients with myeloma.Blood112(7) , 2878–2885 (2008).
  • Radhakrishnan S , CabreraR, SchenkELet al.: Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo.J. Immunol.181(5) , 3137–3147 (2008)
  • Idler I , GiannopoulosK, ZenzTet al.: Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.Br. J. Haematol. DOI: 10.1111/j.1365-2141.2009.08014.x (2009)(Epub ahead of print).
  • Kryczek I , WeiS, SzeligaW, VatanL, ZouW: Endogenous IL-17 contributes to reduced tumor growth and metastasis.Blood114(2) , 357–359 (2009).
  • Wang L , YiT, KortylewskiM, PardollDM, ZengD, YuH: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway.J. Exp. Med.206(7) , 1457–1464 (2009).
  • Murugaiyan G , SahaB: Protumor vs antitumor functions of IL-17.J. Immunol.183(7) , 4169–4175 (2009).
  • Sato K , SuematsuA, OkamotoKet al.: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.J. Exp. Med.203(12) , 2673–2682. (2006).
  • Daynes RA , AraneoBA: Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4.Eur. J. Immunol.19(12) , 2319–2325 (1989).
  • Porrata LF , InwardsDJ, AnsellSMet al.: Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.Biol. Blood Marrow Transplant.14(7) , 807–816 (2008).
  • Zinser E , RössnerS, LittmannLet al.: Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo.Immunobiology214(9–10) , 843–851 (2009).
  • Arpinati M , ChirumboloG, NicoliniB, AgostinelliC, RondelliD: Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib(Velcade).Bone Marrow Transplant.43(3) , 253–259 (2009).
  • Basler M , LauerC, BeckU, GroettrupM: The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.J. Immunol.183(10) , 6145–6150.(2009)
  • Quach H , HsuA, RitchieDet al.: In vivo antagonistic effects of dexamethasone on lenalidomide-induced NK cell activation.Blood114 (2009)(Abstract 1639).
  • Rajkumar SV , JacobusS, CallanderNSet al.: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.Lancet Oncol. doi:10.1016/S1470-2045(09)70284-0 (2009) (Epub ahead of print).
  • Augustson BM , BegumG, DunnJAet al.: Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Reseach Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party.J. Clin. Oncol.23 , 9219–9226 (2005).
  • Goodyear O , PiperK, KhanNet al.: CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden.Blood106(13) , 4217–4224 (2005).
  • Moshitsky S , KukulanskyT, HaimovichJet al.: Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.Immunol. Cell Biol.86(3) , 261–267 (2008).
  • Cohen S , HaimovichJ, HollanderN: B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.J. Immunother.28(5) , 461–466 (2005).
  • Bergenbrant S , YiQ, OsterbergAet al.: Modulation of anti-idiotypic immune response by immunization with autologous M-component protein in multiple myeloma patients.Br. J. Harmatol.92(4) , 840–846 (1996).
  • Osterberg A , YiQ, HenrikssonLet al.: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.Blood91(7) , 2459–2466 (1998).
  • Rasmussen T , HanssonL, OsterbergAet al.: Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.Blood101(11) , 4607–4610 (2003).
  • Hansson L , AbdallaAO, MoshfeghAet al.: Long-term idiotype vaccination combined with interleukin-12(IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.Clin. Cancer Res.13(5) , 1503–1510 (2007).
  • Dhodapkar MV , OsmanK, Teruya-FeldsteinJet al.: Expression of cancer/testis(CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.Cancer Immun.23(3) , 9 (2003).
  • Qian J , XieJ, HongSet al.: Dickkopf-1(DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.Blood110(5) , 1587–1594 (2007).
  • Wang W , NishiokaY, OxakiSet al.: HM1.24(CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 -antibody.Cancer Immunol. Immunother.58(6) , 967–976 (2009).
  • Kawano T , AhmadR, NogiHet al.: MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.Int. J. Oncol.33(1) , 153–159 (2008)
  • Goodyear OC , PrattG, McLarnon et al.: Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undertermined significance (MGUS) and multiple myeloma. Blood112(8) , 3362–3372 (2008).
  • Curioni-Fontecedro A , KnightsAJ, TinguelyMet al.: MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma.Leukemia22(8) , 1646–1648 (2008).
  • Tinguely M , JenniB, KnightsAet al.: MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome.Cancer Sci.99(4) , 720–725 (2008).
  • Szmania S , GnjaticS, TricotGet al.: Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.J. Immunother.30(8) , 847–854 (2007).
  • Dabadghao S , BergenbrantS, AntonDet al.: Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells.Br. J. Haematol.100(4) , 647–654 (1998).
  • Liso A , Stockerl-GoldsteinKE, Aufferman-GretzingerSet al.: Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.Biol. Blood Marrow Transplant.6(6) , 621–627 (2000).
  • Reichardt VL , MilazzoC, BruggerWet al.: Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.Haematalogica88(10) , 1139–1149 (2003).
  • Lacy MQ , MandrekarS, DispenzieriAet al.: Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.Am. J. Hematol.84(12) , 799–802 (2009).
  • Banerjee DK , DhodapkarMV, MatayevaEet al.: Expansion of FOXP3high regulatory T cell by human dendritic cells(DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.Blood108(8) , 2655–2661 (2006).
  • Anderson KC : Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.Exp. Hematol.35(4 Suppl. 1) , 155–162 (2007).
  • Hayashi T , HideshimaT, AkiyamaMet al.: Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.Blood102(4) , 1435–1442 (2003).
  • Lee JJ , ChoiBH, KangHKet al.: Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.Leuk. Lymphoma48(10) , 2022–2031 (2007)
  • Rapoport AP , StadmauerEA, AquiNet al.: Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.Nat. Med.11(11) , 1230–1237. (2005).
  • Gahrton G , TuraS, LjungmanPet al.: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.J. Clin. Oncol.13 , 1312–1322 (1995).
  • Gahrton G , TunaS, LjungmanPet al.: Allogeneic bone marrow transplantation in multiple myeloma.N. Engl. J. Med.325 , 1267–1273 (1991).
  • Crawley C , IacobelliS, BjörkstrandBet al.: Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.Blood109 , 3588–3594 (2007).
  • Bensinger WI , BucknerCD, AnasettiCet al.: Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome.Blood88 , 2787–2793 (1996).
  • Tricot G , VesoleDH, JagannathSet al.: Graft-versus-myeloma effect: proof of principle.Blood87(3) , 1196–1198 (1996).
  • Zeiser R , BertzH, SpyridonidisAet al.: Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives.Bone Marrow Transplant.34(11) , 923–928 (2004).
  • Verdonck LF , LokhorstHM, DekkerAWet al.: Graft-versus-myeloma effect in two cases.Lancet347(9004) , 800–801 (1996).
  • Lokhorst HM , SchattenbergA, CornelissenJJet al.: Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.J. Clin. Oncol.18(16) , 3031–3037 (2000).
  • Björkstrand BB , LjungmanP, SvenssonHet al.: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood Marrow Transplantation.Blood88(12) , 4711–4718 (1996).
  • Bruno B , RottaM, PatriarcaFet al.: Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.Blood113(14) , 3375–3382 (2009).
  • Bruno B , RottaM, PatriarcaFet al.: A comparison of allografting with autografting for newly diagnosed myeloma.N. Engl. J. Med.356(11) , 1110–1120 (2007).
  • Kapp M , StevanovićS, FickKet al.: CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT.Bone Marrow Transplant.43(5) , 399–410 (2009).
  • Yi Q , OsterborgA, BergenbrantSet al.: Idiotype-reactive T-cell subsets and tumour load in monoclonal gammopathies.Blood86(8) , 3043–3049 (1995).
  • van Rhee F , SzmaniaSM, ZhanFet al.: NY-ESO-I is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.Blood105(10) , 3939–3944 (2005).
  • Bernal M , GarridoP, JiménezPet al.: Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells.Hum. Immunol.70(10) , 854–857 (2009).
  • Zheng C , OstadM, AnderssonMet al.: Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma.Br. J. Haematol.118(3) 778–785 (2002).
  • Frohn C , HoppnerM, SchlenkePet al.: Anti-myeloma activity of natural killer lymphocytes.Br. J. Haematol.119(3) , 660–666 (2002).
  • Alici E , KonstantinidisKV, SutluTet al.: Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model.Exp. Hematol.35(12) , 1839–1846 (2007).
  • Alici E , SutluT, BjorkstrandBet al.: Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.Blood111(6) , 3155–3162 (2008).
  • Gattinoni L , PowellDJ Jr, Rosenberg SA et al.: Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol.6(5) , 383–393 (2006).
  • Noonan K , MatsuiW, SerafiniPet al.: Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.Cancer Res.65(5) , 2026–2034 (2005).
  • Rosenberg SA , YannelliJR, YangJCet al.: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.J. Natl Cancer Inst.86(15) , 1159–1166 (1994).
  • Rosenberg SA , DudleyME: Adoptive cell therapy for the treatment of patients with metastatic melanoma.Curr. Opin. Immunol.21(2) , 233–240 (2009).
  • Westwood JA , SmythMJ, TengMWet al.: Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.Proc. Natl Acad. Sci. USA102(52) , 19051–19056 (2005).
  • Scott AM , TebbuttN, LeeFTet al.: A Phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.Clin. Cancer Res.13(11) , 3286–3292 (2007).
  • Hideshima T , BergsagelPL, KuehlWMet al.: Advances in biology of multiple myeloma: clinical applications.Blood104(3) , 607–618 (2004).
  • Quach H , RitchieD, StewartAKet al.: Mechanism of action of immunomodulatory drugs(IMiDS) in multiple myeloma.Leukemia DOI: 10.1038/leu.2009.236 (2009) (Epub ahead of print).
  • Corral LG , HaslettPA, MullerGWet al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α.J. Immunol.163(1) , 380–386 (1999).
  • LeBlanc R , HideshimaT, CatleyLPet al.: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.Blood103(5) , 1787–1790 (2004).
  • Haslett PA , CorralLG, AlbertM, KaplanG: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.J. Exp. Med.187(11) , 1885–1892 (1998).
  • Schafer PH , GandhiAK, LovelandMAet al.: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.J. Pharmacol. Exp. Ther.305(3) , 1222–1232 (2003).
  • Galustian C , MeyerB, LabartheMCet al.: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.Cancer Immunol. Immunother.58(7) , 1033–1045 (2009).
  • Dredge K , MarriottJB, TodrykSMet al.: Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.J. Immunol.168(10) , 4914–4919 (2002).
  • Kronenberg M : Toward an understanding of NKT cell biology: progress and paradoxes.Annu. Rev. Immunol.23 , 877–900 (2005).
  • Davies FE , RajeN, HideshimaTet al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.Blood98(1) , 210–216 (2001).
  • Galustian C , KlaschkaD, LabartheMC, BartlettJB, DalgleishAG: The immunomodulatory drug (IMID®) CC-4047 enhances the proliferation and anti-tumour fuction of γ δ T cells.J. Immunother.27 , S50 (2004).
  • Hayashi T , HideshimaT, AkiyamaMet al.: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.Br. J. Haematol.128(2) , 192–203 (2005).
  • Chang DH , LiuN, KlimekVet al.: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.Blood108(2) , 618–621 (2006).
  • Fujii S , ShimizuK, SteinmanRM, DhodapkarMV: Detection and activation of human Vα24+ natural killer T cells using a-galactosyl ceramide-pulsed dendritic cells.J. Immunol. Methods272(1–2) , 147–159 (2003).
  • Carnaud C , LeeD, DonnarsOet al.: Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells.J. Immunol.163(9) , 4647–4650 (1999).
  • Smyth MJ , CroweNY, PellicciDGet al.: Sequential production of interferon-γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide.Blood99(4) , 1259–1266 (2002).
  • Eberl G , MacDonaldHR: Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells.Eur. J. Immunol.30(4) , 985–992 (2000).
  • Eberl G , BrawandP, MacDonaldHR: Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation.J. Immunol.165(8) , 4305–4311 (2000).
  • Wu L , AdamsM, CarterTet al.: lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.Clin. Cancer Res.14(14) , 4650–4657 (2008).
  • Dallegri F , PatroneF, FrumentoG, SacchettiC: Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms.J. Natl Cancer Inst.73(2) , 331–339 (1984).
  • Tai YT , LiXF, CatleyLet al.: Immunomodulatory drug lenalidomide(CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.Cancer Res.65(24) , 11712–11720 (2005).
  • Hernandez-Ilizaliturri FJ , ReddyN, HolkovaB, OttmanE, CzuczmanMS: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.Clin. Cancer Res.11(16) , 5984–5992 (2005).
  • Lapalombella R , YuB, TriantafillouGet al.: Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.Blood112(13) , 5180–5189 (2008).
  • Roda JM , PariharR, MagroC, NuovoGJ, TridandapaniS, CarsonWE 3rd: Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res.66(1) , 517–526 (2006).
  • Green DR , FergusonT, ZitvogelL, KroemerG: Immunogenic and tolerogenic cell death.Nat. Rev. Immunol.9(5) , 353–363 (2009).
  • Panaretakis T , JozaN, ModjtahediNet al.: The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death.Cell Death Differ.15(9) , 1499–1509 (2008).
  • Zitvogel L , ApetohL, GhiringhelliF, KroemerG: Immunological aspects of cancer chemotherapy.Nat. Rev. Immunol.8(1) , 59–73 (2008).
  • Karin M , YamamotoY, WangQM: The IKK NF-κ B system: a treasure trove for drug development.Nat. Rev. Drug Discov.3(1) , 17–26 (2004).
  • Li ZW , ChenH, CampbellRA, BonavidaB, BerensonJR: NF-κB in the pathogenesis and treatment of multiple myeloma.Curr. Opin. Hematol.15(4) , 391–399 (2008).
  • Spisek R , CharalambousA, MazumderA, VesoleDH, JagannathS, DhodapkarMV: Bortezomib enhances dendritic cell(DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.Blood109(11) , 4839–4845 (2007).
  • Chatterjee M , ChakrabortyT, TassoneP: Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy.Eur. J. Cancer42(11) , 1640–1652 (2006).
  • Klein B , ZhangXG, JourdanMet al.: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-l.Blood73 , 517–526 (1989).
  • Vink A , CoulieP, WarnierGet al.: Mouse plasmacytoma growth in vivo: enhancement by interleukin 6(IL-6) and inhibition by antibodies directed against IL-6 or its receptor.J. Exp. Med.172(3) , 997–1000 (1990).
  • van Zaanen HC , LokhorstHM, AardenLAet al.: Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a Phase I dose-escalating study.Br. J. Haematol.102(3) , 783–790 (1998).
  • Podar K , RichardsonPG, ChauhanD, AndersonKC: Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.Expert Rev. Anticancer Ther.7(4) , 551–566 (2007).
  • Kastritis E , CharidimouA, VarkarisA, DimopoulosMA: Targeted therapies in multiple myeloma.Target Oncol.4(1) , 23–36 (2009).
  • Prince HM , HönemannD, SpencerAet al.: Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a Phase 2 study of pazopanib (GW786034).Blood113(19) , 4819–4820 (2009).
  • Tai YT , LiXF, CatleyLet al.: Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.Cancer Res.65(24) , 11712–11720 (2005).
  • Uno T , TakedaK, KojimaYet al.: Eradication of established tumors in mice by a combination antibody-based therapy.Nat. Med.12(6) , 693–698 (2006).
  • Hilchey SP , HyrienO, MosmannTRet al.: Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a ‘vaccinal effect‘ of rituximab.Blood113 , 3809–3812 (2009).
  • Ayuk F , ZanderA, KrögerN: Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma.Ann. Hematol.88(5) , 401–404 (2009).
  • Coscia M , MarianiS, BattaglioSet al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukaemia 18 , 139–145 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.